
|Videos|November 17, 2016
- NSCLC (Issue 11)
- Volume 4
- Issue 2
Clinical Trials Exploring Bevacizumab in NSCLC
Author(s)Catherine Shu, MD
Catherine Shu, MD, medical oncologist, Division of Hematology/Oncology, Columbia University Medical Center, discusses two clinical trials exploring the use of bevacizumab (Avastin) in patients with non-small cell lung cancer.
Advertisement
Articles in this issue
about 9 years ago
Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLCabout 9 years ago
Expert Explores Treatments for Biomarker-Negative Lung Cancerabout 9 years ago
Erlotinib/Bevacizumab Combo Warrants Consideration for EGFR+ NSCLCabout 9 years ago
The Significance of Surgery Quality in NSCLCabout 9 years ago
Practice-Changing Translational Advances Predicted for NSCLCabout 9 years ago
Addressing the Challenges of Treating Non-Driver NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5







































